AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Ion Beam Applications, SA

Major Shareholding Notification Jan 12, 2018

3960_mrq_2018-01-12_87e7af7b-6723-460b-bf5f-2e7f7173a456.pdf

Major Shareholding Notification

Open in Viewer

Opens in native device viewer

IBA – TRANSPARENCY NOTIFICATION

Louvain-la-Neuve, Belgium, January 12, 2018, 17.35 - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on January 12, 2018.

Reason for the notification Upwards crossing of the 3% threshold further to the
acquisition of shares –and thus voting rights- held as
loan collateral
Persons
subject
to
the
notification
IBA SA, issuer
requirement
Persons that dispose of voting rights Kempen Capital Management NV
Transaction date 01/01/2018
Threshold that is crossed (in %) 3%
Upwards crossing further
to the acquisition of
voting rights
Denominator 29 962 246
Voting rights (number) 900 174
Voting rights (%) 3,00%
Chain of control Van Lanschot Kempen N.V. < 100%> F. van
Lanschot Banklers NV <100%> kempen & Co NV
<100%> Kempen Capital Management NV. Kempen
se réfère à la declaration d'indépendance (datée du
15 novembre 2017).
Additional information Kempen Capital Management NV appeals for Art. 11
of the (Transparency) Law (May 2, 2007), by which an
exemption is acquired.

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

For further information, please contact:

IBA

Stephanie Bauwin Legal Counsel +32 10 203 924 [email protected]

Press release | 12/01/2018

Talk to a Data Expert

Have a question? We'll get back to you promptly.